Team Metabolic Health

This is an excerpt of the Health Rounds newsletter, where we present latest medical studies twice a week. To receive it in your inbox for free sign up here, opens new tab

Eli Lilly’s (LLY.N), opens new tab experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo 

Researchers reported, opens new tab at the recent European Society of Cardiology meeting in London that Lilly’s retatrutide significantly reduced patients’ blood lipid levels and cardiovascular risks in a mid-stage trial.

At 48 weeks, for example, retatrutide had reduced levels of triglycerides by up to 40.6%, and levels of a protein called apoC-III involved in glucose metabolism and inflammation by 38%.

Lilly had earlier announced that in the same trial patients taking injections of retatrutide at the highest dose had lost roughly 24% of their body weight, exceeding what the current popular weight-loss drugs demonstrated in clinical trials.

Credit: Reuters